Experience

Mortara Instrument

• United States
• Medical Equipment Manufacturing
• 1 - 100 Employee

• Business Unit Manager

  • Jan 2017 - Present



Translumina

• Germany
• Medical Equipment Manufacturing
• 1 - 100 Employee

• Business Director

  • Mar 2015 - Dec 2016

  It was a step up in my career path as in this time I was responsible for every step of the organization process, and also responsible for profit and loss of the company and how to ensure that the business doing well for the share holders and CEO It was a step up in my career path as in this time I was responsible for every step of the organization process, and also responsible for profit and loss of the company and how to ensure that the business doing well for the share holders and CEO



CR Bard - Europe, Middle East and Africa (EMEA)

• United Kingdom
• Medical Device
• 1 - 100 Employee

• Business Development Manager

  • Oct 2013 - Mar 2015

  Bard was out of the Egyptian market for years as the old agent in Egypt was low profile agent in the field of cardiovascular, so it was a great challenge to launch the Bard products again in Egypt as Bard has a full range of products dealing with many indications with innovating specifications, and we succeed to take about 20% market share after one year Bard was out of the Egyptian market for years as the old agent in Egypt was low profile agent in the field of cardiovascular, so it was a great challenge to launch the Bard products again in Egypt as Bard has a full range of products dealing with many indications with innovating specifications, and we succeed to take about 20% market share after one year



BIOTRONIK

• Germany
• Medical Equipment Manufacturing
• 700 & Above Employee

• Sales and Marketing Manager

  • Sep 2012 - Oct 2013

  Launching of Biotronik Drug Eluting Stent (Orsiro) for the first time in Egypt and how we can position this innovative product to take its healthy market share regarding of the strong competition in the Egyptian market which is price oriented market Launching of Biotronik Peripheral product range (4F Solutions) and 0.018" self-expandable Stent for the first time in the market Launching of Biotronik Drug Eluting Stent (Orsiro) for the first time in Egypt and how we can position this innovative product to take its healthy market share regarding of the strong competition in the Egyptian market which is price oriented market Launching of Biotronik Peripheral product range (4F Solutions) and 0.018" self-expandable Stent for the first time in the market



Boston Scientific

• United States
• Medical Equipment Manufacturing
• 700 & Above Employee

• Product Manager

  • Mar 2009 - Sep 2012

  Responsible for launching new products as Promus Elemen, Training of the team for delivering the scientific messages of Boston products, arranging of workshops and group meetings in different big accounts presenting the full range of the Boston products of Cardiology to take the healthy market share in the Egyptian market Responsible for launching new products as Promus Elemen, Training of the team for delivering the scientific messages of Boston products, arranging of workshops and group meetings in different big accounts presenting the full range of the Boston products of Cardiology to take the healthy market share in the Egyptian market



OrbusNeich Medical Company Ltd.

• Hong Kong
• Medical Equipment Manufacturing
• 1 - 100 Employee

• Clinical Specialist

  • Jan 2007 - Mar 2009

  Responsible for launching of a new concept in field of Drug Eluting Stent which called Biological Stent (Genus Stent) which depends on acceleration of arterial healing after stenting by helping of a normal mechanism depending on endothelial progenator cells (EPC) (Bone Marrow Cells) aiming to reduce the period the dual anti-platelet therapy Responsible for launching of a new concept in field of Drug Eluting Stent which called Biological Stent (Genus Stent) which depends on acceleration of arterial healing after stenting by helping of a normal mechanism depending on endothelial progenator cells (EPC) (Bone Marrow Cells) aiming to reduce the period the dual anti-platelet therapy